全球伴侶動物用藥品市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計到 2034 年，伴侶動物藥品市場規模將從 2025 年的 198.4 億美元成長至 320.1 億美元，2026 年至 2034 年的複合年成長率為 5.46%。

隨著全球寵物飼養量的持續成長以及人們對寵物健康和福利的日益關注，伴侶動物藥品市場預計將迎來顯著成長。飼主越來越將寵物視為家庭成員，因此對包括疫苗、驅蟲藥和疼痛管理方案在內的獸藥的需求激增。預防性醫療保健重要性和定期獸醫檢查必要性的日益增強，進一步加速了這一趨勢。隨著市場的發展，製藥公司可能會加大研發投入，開發針對伴侶動物特定健康需求的創新治療方法，確保未來穩健成長。

此外，獸醫學和技術的進步正在提升伴侶動物藥物的功能。標靶治療和生物製藥的研發正在改變治療格局，為管理各種寵物健康問題提供更有效、更安全的選擇。同時，遠端醫療在獸醫學領域的普及也促進了藥物的獲取，使飼主能夠遠端諮詢獸醫並更便捷地獲得所需藥物。隨著市場不斷適應這些技術進步，對創新和可近性的關注將推動伴侶動物藥物產業的成長。

此外，人們對寵物健康促進和預防醫學的日益關注正在影響伴侶動物藥品市場。飼主越來越傾向於選擇能夠促進寵物整體健康和延長壽命的產品。營養補充品以及支持關節健康、皮膚毛髮狀況和消化健康的補充品正受到消費者的青睞。隨著市場的發展，藥品與保健產品的融合將為製造商提供新的機遇，以滿足伴侶動物的全面健康需求。著眼於創新、普及和消費者教育，伴侶動物藥品市場的未來前景光明，為改善寵物照護解決方案鋪平了道路。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球伴侶動物用藥品市場：依動物類型分類

• 市場分析、洞察與預測
• 狗
• 貓
• 馬

第5章 全球伴侶動物用藥品市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射藥物
• 局部行政部門

第6章 全球伴侶動物用藥品市場：依產品分類

• 市場分析、洞察與預測
• 製藥
• 疫苗
• 藥用飼料添加劑

第7章 全球伴侶動物用藥品市場：依藥物類別分類

• 市場分析、洞察與預測
• 抗生素
• 抗發炎藥
• 預防犬心絲蟲的藥物
• 殺蟲劑
• 營養補充品
• 行為藥物
• 疫苗
• 其他

第8章 全球伴侶動物用藥品市場：依通路分類

• 市場分析、洞察與預測
• 動物醫院
• 診所

第9章 全球伴侶動物用藥品市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Boehringer Ingelheim International GmbH
  • Ceva
  • Balchem Corp
  • Chanelle Pharma
  • Dechra Pharmaceuticals Limited
  • Elanco Or Its Affiliates
  • ECO-Animal Health Ltd
  • Enovis Corporation
  • Invetx
  • Merck & Co. Inc
  • MP Agro Co. Ltd
  • Neogen Corporation
  • Norbrook
  • Orion Corporation
  • Sumitomo Corporation

The Companion Animal Pharmaceuticals Market size is expected to reach USD 32.01 Billion in 2034 from USD 19.84 Billion (2025) growing at a CAGR of 5.46% during 2026-2034.

The companion animal pharmaceuticals market is poised for significant growth as pet ownership continues to rise globally, leading to an increased focus on the health and well-being of pets. As pet owners increasingly view their animals as family members, the demand for veterinary medicines, including vaccines, anti-parasitics, and pain management solutions, is surging. This trend is further fueled by the growing awareness of preventive healthcare and the importance of regular veterinary check-ups. As the market evolves, pharmaceutical companies are likely to invest in research and development to create innovative treatments that address the specific health needs of companion animals, ensuring a robust trajectory for future growth.

Moreover, advancements in veterinary medicine and technology are enhancing the capabilities of companion animal pharmaceuticals. The development of targeted therapies and biologics is revolutionizing the treatment landscape, offering more effective and safer options for managing various health conditions in pets. Additionally, the rise of telemedicine in veterinary care is facilitating access to pharmaceuticals, allowing pet owners to consult with veterinarians remotely and obtain necessary medications more conveniently. As the market continues to adapt to these technological advancements, the focus on innovation and accessibility will drive growth in the companion animal pharmaceuticals sector.

Furthermore, the increasing emphasis on pet wellness and preventive care is influencing the companion animal pharmaceuticals market, as pet owners seek products that promote overall health and longevity. Nutraceuticals and supplements designed to support joint health, skin and coat condition, and digestive health are gaining popularity among consumers. As the market evolves, the integration of pharmaceuticals with wellness products will create new opportunities for manufacturers to cater to the holistic health needs of companion animals. With a focus on innovation, accessibility, and consumer education, the future of the companion animal pharmaceuticals market looks promising, paving the way for enhanced pet care solutions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Animal Type

• Dogs
• Cats
• Horses

By Route of Administration

• Oral
• Injectable
• Topical

By Product

• Drugs
• Vaccines
• Medicated Feed Additives

By Drug Class

• Antibiotics
• Anti-inflammatory
• Heart Worm Drugs
• Parasiticides
• Nutritional Drugs
• Behavioral Drugs
• Vaccines
• Others

By Distribution Channel

• Veterinary Hospitals
• Clinics

COMPANIES PROFILED

• Boehringer Ingelheim International GmbH, Ceva, Balchem Corp, Chanelle Pharma, Dechra Pharmaceuticals Limited, Elanco or its affiliates, ECO Animal Health Ltd, Enovis Corporation, Invetx, Merck Co Inc, MP Agro Co Ltd, Neogen Corporation, Norbrook, Orion Corporation, Sumitomo Corporation

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET: BY ANIMAL TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Animal Type
• 4.2. Dogs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Cats Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Horses Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Product
• 6.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Medicated Feed Additives Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Drug Class
• 7.2. Antibiotics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Anti-inflammatory Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Heart Worm Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Parasiticides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Nutritional Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.7. Behavioral Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.8. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Veterinary Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Animal Type
  • 9.2.2 By Route Of Administration
  • 9.2.3 By Product
  • 9.2.4 By Drug Class
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Animal Type
  • 9.3.2 By Route Of Administration
  • 9.3.3 By Product
  • 9.3.4 By Drug Class
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Animal Type
  • 9.4.2 By Route Of Administration
  • 9.4.3 By Product
  • 9.4.4 By Drug Class
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Animal Type
  • 9.5.2 By Route Of Administration
  • 9.5.3 By Product
  • 9.5.4 By Drug Class
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Animal Type
  • 9.6.2 By Route Of Administration
  • 9.6.3 By Product
  • 9.6.4 By Drug Class
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL COMPANION ANIMAL PHARMACEUTICALS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Boehringer Ingelheim International GmbH
  • 11.2.2 Ceva
  • 11.2.3 Balchem Corp
  • 11.2.4 Chanelle Pharma
  • 11.2.5 Dechra Pharmaceuticals Limited
  • 11.2.6 Elanco Or Its Affiliates
  • 11.2.7 ECO - Animal Health Ltd
  • 11.2.8 Enovis Corporation
  • 11.2.9 Invetx
  • 11.2.10 Merck & Co. Inc
  • 11.2.11 MP Agro Co. Ltd
  • 11.2.12 Neogen Corporation
  • 11.2.13 Norbrook
  • 11.2.14 Orion Corporation
  • 11.2.15 Sumitomo Corporation